Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Operating Margin (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Operating Margin for 9 consecutive years, with 7694.9% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Operating Margin fell 244439.0% year-over-year to 7694.9%, compared with a TTM value of 8435.45% through Jun 2025, down 211536.0%, and an annual FY2025 reading of 5219.12%, up 349086.0% over the prior year.
  • Operating Margin was 7694.9% for Q2 2025 at VYNE Therapeutics, down from 4552.97% in the prior quarter.
  • Across five years, Operating Margin topped out at 3234.58% in Q2 2021 and bottomed at 27531.03% in Q4 2022.
  • Average Operating Margin over 5 years is 7907.02%, with a median of 6255.66% recorded in 2022.
  • The sharpest move saw Operating Margin plummeted -2429111bps in 2022, then skyrocketed 1854156bps in 2023.
  • Year by year, Operating Margin stood at 3239.93% in 2021, then tumbled by -750bps to 27531.03% in 2022, then skyrocketed by 67bps to 8989.47% in 2023, then plummeted by -69bps to 15202.38% in 2024, then soared by 49bps to 7694.9% in 2025.
  • Business Quant data shows Operating Margin for VYNE at 7694.9% in Q2 2025, 4552.97% in Q1 2025, and 15202.38% in Q4 2024.